NCT06546553 - A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

October 21, 2025

Study Completion Date

October 21, 2025

Conditions

NeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaColorectal CarcinomaOvarian Carcinoma

Interventions

DRUG

PF-07826390

PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

BIOLOGICAL

sasanlimab

A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

OTHER

SOC (anti-PD-1 + platinum -based chemo)

Standard of Care (anti-PD-1 + platinum -based chemo)

Trial Locations (7)

22031

Virginia Cancer Specialists, Fairfax

32827

Florida Cancer Specialists, Orlando

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

49546

START Midwest, Grand Rapids

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

84119

START Mountain Region, West Valley City

90211

Beverly Hills Cancer Center, Beverly Hills